Keppra levetiracetam APPROVED
Drug Profile
ModalitySmall molecule
RouteOral/IV
Therapy AreaNeurology
Launch1999-11-30
US LOE2009-01-01
Peak Sales Est$500M
Formulations[{"id":"keppra-oral","doses":"250mg, 500mg, 750mg, 1000mg","route":"PO","device":"Tablet/oral soluti
Companies
UCB (ORIGINATOR)100%
Mechanism: SV2A ligand
Expert: High-affinity ligand for synaptic vesicle protein 2A (SV2A), modulating neurotransmitter release and exhibiting antiepileptic activity through a novel mechanism.
Everyday: Binds to a protein in brain cells that helps control the release of brain chemicals, reducing seizures.
Targets: ["SV2A"]
Revenue History
PeriodRevenue ($M)
2023$412M
2024$385M
Programs (1)
IndicationStageKey StudyRegional Status
Focal onset seizuresAPPROVEDE041/046[{"stage":"APPROVED","region":"US","approval_date":"1999-11"},{"stage":"APPROVED
Notes
Levetiracetam, a first-line anticonvulsant targeting SV2A for partial-onset and generalized seizures. Widely used due to minimal drug interactions and broad efficacy; available in IV, oral, and extended-release formulations.
Data from Supabase · Updated 2026-03-24